Form 4: APLT CFO Funtleyder Granted 150K RSUs, Ownership Adjusted

Applied Therapeutics' CFO, Leslie D. Funtleyder, was granted 150,000 Restricted Stock Units, increasing total beneficial ownership to 1,190,459 shares after correcting a prior administrative error.

Summary

• Leslie D. Funtleyder, Chief Financial Officer and Director of Applied Therapeutics, Inc. (APLT), was granted 150,000 compensatory Restricted Stock Units (RSUs).
• These RSUs were issued under the company's 2019 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of APLT common stock.
• The RSUs will vest in equal monthly installments over a 24-month period, commencing on October 1, 2025, contingent upon Funtleyder's continued service.
• Following this transaction, Funtleyder's total beneficial ownership of common stock is 1,190,459 shares.
• The reported total holdings have been adjusted to correct an administrative error in previous Form 4 filings that resulted in an understatement of the total beneficial ownership.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally positive for aligning interests and retention. The correction of a prior administrative error, while indicating past inaccuracy, improves current transparency. No negative operational or financial news is present.

Positives

• The grant of 150,000 Restricted Stock Units to a key executive like the CFO aligns management incentives with long-term shareholder interests.
• The 24-month vesting schedule encourages executive retention and sustained performance over time.
• The correction of an administrative error in prior Form 4s enhances transparency and accuracy in reporting beneficial ownership.

Negatives

• The grant price of $0 for the RSUs means there is no direct cash outlay by the executive for these shares initially, which could be perceived differently than an open market purchase.
• The existence of an administrative error in prior Form 4s, while corrected, indicates past inaccuracies in reporting.

Risks

• The ultimate value of the granted RSUs is directly tied to the future market performance of Applied Therapeutics' common stock, exposing the executive to market volatility.
• The vesting of the RSUs is contingent on continued service, meaning the executive could forfeit unvested units if employment ceases before the vesting schedule is complete.

Future Outlook

The vesting schedule for the granted RSUs extends over the next 24 months from October 1, 2025, indicating a continued commitment from the Chief Financial Officer to the company's long-term performance and strategic objectives.

Industry Context

Executive compensation, particularly through equity grants like Restricted Stock Units, is a standard practice across the biotechnology and pharmaceutical industries. This strategy is commonly employed to attract, retain, and incentivize key talent, aligning the interests of executives with long-term shareholder value creation, which is crucial in growth-oriented sectors.

Comparison to Industry Standards

• The grant of compensatory RSUs with a vesting schedule is a common executive compensation practice, comparable to similar grants observed at peer biotechnology companies such as BioNTech SE or Moderna, Inc., which frequently use equity to incentivize leadership.
• A $0 grant price for RSUs is standard, as these represent a right to receive shares upon vesting, rather than an option to purchase.
• The 24-month vesting period is within typical industry ranges for executive equity awards, often seen in companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, designed to promote long-term retention and performance.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term company performance; improved transparency from the correction of a prior reporting error.
• Employees: May signal stability in executive leadership and continued commitment to the company's equity incentive plan.

Next Steps

• The 150,000 RSUs will vest in equal monthly installments over 24 months, starting October 1, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive and a correction of a prior administrative error in beneficial ownership reporting. While positive for executive retention and transparency, it does not contain new operational, financial, or strategic information that would fundamentally alter the investment thesis for Applied Therapeutics. Therefore, a 'hold' recommendation is appropriate, pending further substantive company updates.

Keywords

Applied Therapeutics, APLT, Form 4, SEC Filing, Restricted Stock Units, RSUs, Executive Compensation, Insider Transaction, Leslie D. Funtleyder, CFO, Equity Incentive Plan, Beneficial Ownership